RG6561 / Roche - LARVOL DELTA

Another phase 1 drug sunk by early data is FAP-LTBR, also known as RG6221, a LTBR agonist in development for solid tumors. (FierceBiotech) - "'The current dataset from the phase 1 trial suggests that continued enrollment is highly unlikely to generate results that justify further clinical development of the molecule.'....The final asset to be dumped today was another solid tumor drug called RG6561."

Discontinued • Solid Tumor

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=12 | Terminated | Sponsor: Genentech, Inc. | N=310 ➔ 12 | Trial completion date: Feb 2027 ➔ Nov 2025 | Suspended ➔ Terminated | Trial primary completion date: Feb 2027 ➔ Nov 2025; Following a thorough review of safety data, preliminary efficacy data and an evaluation of overall risk-benefit, Sponsor made the decision to end the study.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Solid Tumor

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=310 | Suspended | Sponsor: Genentech, Inc. | Recruiting ➔ Suspended

Trial suspension • Solid Tumor

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=310 | Recruiting | Sponsor: Genentech, Inc. | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Metastases • Oncology • Solid Tumor

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=310 | Not yet recruiting | Sponsor: Genentech, Inc.

Combination therapy • Metastases • New P1 trial • Oncology • Solid Tumor